Business Wire

With Intelligence Announces That Motive Partners Has Acquired a Majority Stake

20.7.2023 10:30:00 EEST | Business Wire | Press release

Share

With Intelligence, a leading provider of investment data and intelligence for allocating, fund-raising and business development in the public and private markets, announced that it has received a majority investment from funds advised by Motive Partners (“Motive”), a specialist private equity firm focused on financial technology. Intermediate Capital Group ("ICG"), who originally invested in With Intelligence in 2020, will invest further alongside Motive. The investment is intended to serve as an accelerant for With Intelligence's growth, as the platform focuses on delivering leading connectivity, data and insights solutions to the Limited Partner and General Partner communities.

Founded in 1998, With Intelligence is a leading provider of data, intelligence and connectivity to the global asset management industry, with an integrated product suite of data, insights and events covering hedge funds, private credit, private equity, real estate and traditional asset management. Established 25 years ago, with over 500 employees and a geographic footprint across Europe, North America and Asia, With Intelligence has seen significant growth in recent years, with over 2,500 customers and a revenue compound annual growth rate of 33%.

With Intelligence blends data from a variety of the platform’s proprietary brands, delivering insights that include profiles, fund information, performance metrics and analyst perspectives. As the alternative investment landscape continues to evolve, With Intelligence is positioned to provide solutions that support mission-critical decision making across the fundraising and allocation lifecycle, for all participants in the value-chain. With Intelligence's strong growth is bolstered by a leading position in the hedge fund market, and is beginning to benefit from significant tailwinds driving the growth of private markets towards an estimated $15 trillion of assets under management in 2027.

Charlie Kerr, Founder & CEO at With Intelligence commented: “There is a huge opportunity for us to serve the global asset management industry during an exciting period of growth with greater data and analytics solutions than presently exist in the market. In order to capitalise on these tailwinds, we have chosen to partner with Motive Partners, who have a strong depth of expertise in financial technology across their group of Investors, Operators and Innovators. I am also grateful to ICG for their continued support and investment in the next phase of our growth journey.”

Neil Cochrane, Partner at Motive Partners commented: “We are positioned at the intersection of two exciting trends - the increase of allocations towards alternatives and the emergence of exciting new analytics and AI technologies to derive insights within the sector. Through the Motive IOI model and our extensive network, we are looking forward to capitalising on this market opportunity in partnership with Charlie, the With Intelligence team, and ICG.”

The investment by Motive and ICG will support With Intelligence to accelerate its data strategy and technology capabilities, continue to develop tailored offerings across various asset classes, grow the private markets offerings, and execute the next phase of the partnership and M&A strategies. It will also enable the company to further accelerate the pace of talent acquisition. Additionally, Motive's integrated operating model ("IOI model"), combining Investors, Operators and Innovators, will see a number of Motive team members collaborate with the With Intelligence team, including Charles Teschner (Industry Partner at Motive and the former CEO of Data and Analytics Solutions at BNY Mellon), Andy Stewart (Industry Partner at Motive, current CEO of Wilshire, and the former Co-Head of Blackrock's Alternative Investment Platform) and a team from Motive's innovation division, Motive Create.

“It has been a privilege to support the With Intelligence management team on their outstanding journey over the past few years, working alongside a visionary and entrepreneurial founder such as Charlie" said Jamie Rivers, Managing Director at ICG. Gareth Knight, Head of European Mid-Market at ICG added: "The company has a proven strategy for growth, and we're delighted to support the business for a further Investment cycle. We see Motive Partners being extremely well placed to help accelerate this over the coming years.”

Global investment banking firm Houlihan Lokey served as financial advisor to With Intelligence on the transaction, with other advisors including Proskauer (Legal), Financial & Tax (Alvarez & Marsal) and OC&C (Commercial). Arrowpoint Advisory, Joelson and Blick Rothenberg supported Management. Motive Partners' financial advisor was Raymond James, and they were also advised by MDW Capital Advisory (Debt Advisor), White & Case (Legal), Plural Strategy, Oliver Wyman (Commercial), and EY (Financial & Tax).

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

With Intelligence
Louise Green, Chief Marketing Officer
louise.green@withintelligence.com

Motive Partners
Sam Tidswell-Norrish, Managing Director
sam@motivepartners.com

ICG
Clare Glynn, Head of Corporate Communications
clare.glynn@icgam.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Venture Global Announces Closing of $1.5 Billion Senior Secured Vessel Financing Facility26.6.2026 23:30:00 EEST | Press release

Venture Global, Inc. (NYSE: VG) announced today that its wholly-owned subsidiary, Venture Global Shipping Holdings, LLC (“VGSH”), has entered into a Credit and Guaranty Agreement providing for a senior secured term loan facility (the “Facility”) in an aggregate principal amount of up to $1,500,000,000. The Facility will mature on June 26, 2032. Deutsche Bank and ING acted as coordinating lead arrangers for the Facility. ING also serves as facility agent and security trustee. VGSH intends to use the net proceeds from the Facility for general corporate purposes, including to reimburse Venture Global LNG, Inc. for payments previously made by it or its affiliates in connection with the acquisition of nine LNG carriers, funding certain reserve accounts, and paying transaction fees and expenses. About Venture Global Venture Global is an American producer and exporter of low-cost U.S. liquefied natural gas (“LNG”) with over 100 MTPA of capacity in production, construction, or development. Ven

Capco Recognized by OpenAI for Innovation and Responsible AI Leadership26.6.2026 21:00:00 EEST | Press release

Global management and technology consultancy Capco, a Wipro company,has been recognized by OpenAI for both AI innovation and responsible AI leadership. Capco received the AI Governance & Risk Excellence Award at the recent OpenAI Partner Summit 2026 in San Francisco, highlighting Capco’s ability to deliver enterprise-grade AI outcomes in highly regulated environments. The award recognizes Capco’s expert advantage when helping financial services and energy organizations to scale AI with confidence, balancing innovation with strong governance to reduce risk, strengthen compliance and improve customer outcomes. This award follows Capco winning the OpenAI Codex Hackathon, where its UK AI Lab competed against more than 30 teams and over 100 participants from across the OpenAI partner ecosystem. Capco's winning entry Sentra – a consulting-led, AI-powered retail banking solution – uses digital twin technology to identify vulnerable customers and recommend explainable next-best actions for fro

Incyte Announces Positive CHMP Opinion for Opzelura ® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 14:30:00 EEST | Press release

Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs) are inadequate or inappropriate. “AD is a chronic skin condition that can have a significant impact on daily life. The positive CHMP opinion for Opzelura marks meaningful progress toward bringing the first non-steroidal topical JAK treatment option to adults in Europe with moderate AD for whom standard topical therapies have failed,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved by the European Commission, Opzelura could help address an important gap for patients who have limited treatment options when TCSs and TCIs are inadequate or inappropriate.” The positive CHMP o

Datroway ® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 14:00:00 EEST | Press release

Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the TROPION-Breast02phase 3 trial, which werepresented at the 2025 European Society for Medical Oncology Congress and published in Annals of Oncology. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In TROPION-Breast02, Datroway demonstrated a

DAYBU ® (trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 13:49:00 EEST | Press release

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating condition," said Catherine Owen Adams, Acadia’s Chief Executive Officer. “Our commitment is to make a meaningful difference in the lives of patients, caregivers, and the wider Rett com

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye